Third time lucky? India sends Sutent case back for fresh review
This article was originally published in Scrip
Executive Summary
Two patent revocations later, Pfizer has received a significant reprieve with India's Intellectual Property Appellate Board (IPAB) sending the case concerning its anticancer, Sutent (sunitinib malate), back to the Controller General of Patents to review the matter afresh.